KRAS and head and neck squamous cell carcinoma: Unlike colorectal cancer, RAS mutations are rarely observed in SCCHN [43], but a 2017 report suggested that some KRAS variants in SCCHN might affect the efficacy of cetuximab or other antitumor drugs [44].